Semaglutide
Semaglutide
Semaglutide
Semaglutide is a human glucagon like peptide-1 analog produced by biological fermentation through gene recombination technology. It stimulates insulin secretion in a glucose dependent manner by mediat
Send Inquiry
Description
Semaglutide
Product Name: Semaglutide CAS No.:910463-68-2 Product origin: Usually produced by recombinant DNA technology Content specification: ≥98% (HPLC) Detection method: RP-HPLC Active ingredient: Semaglutide Product fineness: 100-200 mesh Product properties: White to off-white powder Product packaging: 5mg, 10mg, 15mg, 20mg, 30mg Product storage: Protected from light, dry, cool place, relative humidity ≤60% Shelf life: 24 months |
Products Description
Semaglutide is a human glucagon like peptide-1 analog produced by biological fermentation through gene recombination technology. It stimulates insulin secretion in a glucose dependent manner by mediating the GLP-1 receptor, and is used for blood glucose control in adult patients with type II diabetes.
The long-term mechanism of semaglutide is based on structural modification. Connecting the lysine position at position 26 of the peptide chain to an 18 carbon fatty acid side chain modified carbon chain increases the molecular weight of semaglutide and enhances its affinity for albumin by 5-6 times, avoiding rapid clearance by the kidneys and preventing metabolic degradation, thus prolonging the half-life in vivo.
Products Advantages
Ultra long acting GLP-1 analogs can be made into two dosage forms: oral and injection. Oral preparations can be made once a day, while injection preparations can be made once a week
Produced using biotechnology methods, in compliance with GMP standards, and of comparable quality to the original research product
Products Function
The benefits of Semaglutide to human body mainly focus on its two approved core indications, namely, improving the health status of patients with type 2 diabetes and assisting the management of chronic weight in adults. At the same time, Semaglutide has additional benefits in cardiovascular protection, which can be divided into the following three categories:
1. Core benefits for patients with type 2 diabetes
Effective control of blood sugar with low risk of hypoglycemia
Protecting pancreatic beta cell function and delaying disease progression
Reduce the risk of cardiovascular adverse events
2. Core benefits of weight management
Significant and sustained weight loss, improvement in obesity related indicators
Improve obesity related comorbidities and reduce metabolic risk
Semaglutide can indirectly improve various metabolic abnormalities caused by obesity:
-For patients with combined hypertension, it can assist in lowering blood pressure;
-For patients with concomitant dyslipidemia, triglyceride and low-density lipoprotein cholesterol (LDL-C) levels can be improved;
-For those with "prediabetes", the risk of developing type 2 diabetes can be reduced.
3. Indirect benefits related to medication convenience
Low medication frequency and high patient compliance
Positive impact on weight (for patients with diabetes)
It should be noted that:
The benefits of Semaglutide need to be achieved through standardized medication under the guidance of a doctor, and should be accompanied by dietary control and exercise; At the same time, its use has contraindications (such as contraindications for patients with a history of medullary thyroid cancer) and potential adverse reactions (such as gastrointestinal reactions and thyroid tumor risk warnings), and its applicability must be strictly evaluated according to medical advice. Self medication is not allowed.